NN 9709Alternative Names: NN9709
Latest Information Update: 25 Mar 2017
At a glance
- Originator Novo Nordisk
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 17 Feb 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route) prior to February 2016 (Novo Nordisk's pipeline, February 2016 )